Indication

Graft-versus-host disease

Graft-versus-host disease is a systemic alloimmune complication occurring primarily after allogeneic hematopoietic stem cell transplantation, in which immunocompetent donor T lymphocytes recognize host histocompatibility antigens as foreign and mount an immune attack against recipient tissues. Read more about Graft-versus-host disease

3 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Graft-versus-host disease therapies.

Showing 1–3 of 3 drugs

Filter & compare in the drug finder →Opens the drug finder with Graft-versus-host disease preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Graft-versus-host disease.

Graft-versus-host disease is a systemic alloimmune complication occurring primarily after allogeneic hematopoietic stem cell transplantation, in which immunocompetent donor T lymphocytes recognize host histocompatibility antigens as foreign and mount an immune attack against recipient tissues.

The condition is broadly classified into acute and chronic forms based on clinical presentation and timing.

Acute manifestations characteristically involve maculopapular rash, secretory diarrhea, and cholestatic hepatitis, whereas chronic disease features widespread autoimmune-like inflammation and progressive tissue fibrosis affecting the skin, mouth, eyes, liver, lungs, and musculoskeletal system.

Personalize your experience

Follow Graft-versus-host disease and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it